Braidwell LP Sells 162,894 Shares of Nuvalent, Inc. $NUVL

Braidwell LP decreased its stake in Nuvalent, Inc. (NASDAQ:NUVL) by 13.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,012,982 shares of the company’s stock after selling 162,894 shares during the quarter. Nuvalent makes up 2.6% of Braidwell LP’s portfolio, making the stock its 11th biggest holding. Braidwell LP owned 1.39% of Nuvalent worth $87,603,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Ameriprise Financial Inc. grew its stake in shares of Nuvalent by 8.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 527,050 shares of the company’s stock valued at $45,579,000 after acquiring an additional 42,707 shares during the period. Creative Planning raised its stake in Nuvalent by 30.3% during the 3rd quarter. Creative Planning now owns 22,520 shares of the company’s stock worth $1,948,000 after acquiring an additional 5,232 shares during the period. Freestone Grove Partners LP bought a new stake in Nuvalent during the 3rd quarter worth approximately $342,000. Squarepoint Ops LLC purchased a new position in Nuvalent during the third quarter valued at approximately $642,000. Finally, Wellington Management Group LLP lifted its holdings in Nuvalent by 46.0% during the third quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock valued at $198,979,000 after purchasing an additional 724,491 shares in the last quarter. Institutional investors own 97.26% of the company’s stock.

Nuvalent Stock Performance

NUVL opened at $97.93 on Friday. The stock has a market capitalization of $7.12 billion, a price-to-earnings ratio of -16.74 and a beta of 1.32. The company has a fifty day moving average of $102.97 and a 200 day moving average of $96.94. Nuvalent, Inc. has a fifty-two week low of $55.53 and a fifty-two week high of $113.01.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Barclays set a $152.00 price objective on shares of Nuvalent in a research note on Monday, November 17th. HC Wainwright upped their target price on shares of Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Cantor Fitzgerald increased their price target on Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. JPMorgan Chase & Co. lowered their price objective on Nuvalent from $147.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Finally, Truist Financial set a $140.00 price objective on Nuvalent in a research note on Monday, November 24th. Fifteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $138.67.

Insider Activity

In other news, insider Christopher Durant Turner sold 4,236 shares of Nuvalent stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $412,247.52. Following the sale, the insider directly owned 58,311 shares of the company’s stock, valued at approximately $5,674,826.52. The trade was a 6.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alexandra Balcom sold 4,236 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $97.32, for a total value of $412,247.52. Following the completion of the sale, the chief financial officer owned 84,914 shares in the company, valued at $8,263,830.48. This represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 69,379 shares of company stock valued at $6,940,982. 10.20% of the stock is owned by corporate insiders.

Nuvalent Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.